Trial Profile

An efficacy and safety of Certolizumab in uveitis secondary to Immune-Mediated Inflammatory Diseases patients

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Certolizumab pegol (Primary) ; Immunosuppressants
Indications Anterior uveitis; Behcet's syndrome; Crohn's disease; Intermediate uveitis; Juvenile rheumatoid arthritis; Panuveitis; Polychondritis; Posterior uveitis; Psoriatic arthritis; Reactive arthritis; Rheumatoid arthritis; Spondylarthritis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism
02 Jul 2020 New trial record
06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com